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a b s t r a c t
Limited effectiveness data are available comparing live attenuated influenza vaccine (LAIV) to inactivated
influenza vaccine (TIV) among adults. To compare the incidence of influenza-like illness following immu-
nization of adultswith LAIV vs. TIV,we conducted a retrospective cohort analysis of active componentU.S.
military personnel for the 2005–2006 and 2006–2007 influenza seasons. Recruits experienced a much
higher burden of disease compared to non-recruits, with crude incidence rates of influenza-like illness
2–16 times higher than non-recruits depending on the season and cohort. For both seasons, a slightly
greater protection from influenza-like illness was found for non-recruits who received TIV compared to
LAIV (adjusted incidence rate ratio, 1.17 (95% CI, 1.14–1.20) and 1.33 (95% CI, 1.30–1.36), 2005–2006 and
2006–2007 influenza seasons, respectively). However, for Army and Air Force recruits, LAIV was found
to provide significantly greater protection from influenza-like illnesses compared to TIV, with adjusted
incidence rates of influenza-like illness 22–51% and 18–47% lower among LAIV compared to TIV recipi-
ents for the 2005–2006 and 2006–2007 influenza seasons, respectively. Possible reasons for differences
in recruit and non-recruit findings include differences in pre-existing influenza antibody levels, differing
respiratory disease burden, and/or unmeasured confounding. Consideration of these findings should be
made when developing influenza immunization policies.
© 2009 Elsevier Ltd. All rights reserved.
1. Introduction
A live attenuated influenza vaccine (LAIV) has been licensed
for use in children and adults in the U.S. since 2003. The vac-
cine, which is administered intranasally, represents the first new
approach to influenza vaccines licensed since the development of
split virus vaccines. The injectable trivalent, inactivated influenza
vaccine (TIV) continues to be used regularly in the U.S. and remains
the only option for groups not eligible to receive LAIV. Several
studies have been conducted to evaluate the efficacy and effec-
tiveness of LAIV in comparison to both people receiving TIV and
unvaccinated individuals. However, the majority of these studies
were conducted among children. In children less than 5 years of
age and asthmatic children 6–17 years of age, LAIV was found to
have superior efficacy and effectiveness in comparison to TIV [1–4].
A limited number of studies, mostly randomized trials or exper-
imental challenge studies, have been conducted among adults.
Although both vaccines have been shown to have absolute effec-
tiveness against influenza-like illness in adults, studies directly
∗ Corresponding author. Tel.: +1 301 319 3261; fax: +1 301 319 7620.
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comparing LAIV to TIV found mixed results on which vaccine had
superior efficacy in the prevention of culture-confirmed influenza
[5–9].
Within the U.S. military population, influenza and other respi-
ratory infections have historically caused significant morbidity and
mortality [10–13]. Recruit settings, service on ships, and other mil-
itary settings which require crowding have been associated with
outbreaks of influenza, occasionally despite high immunization
rates [14–17]. The U.S. military has been a strong proponent for
the development and use of influenza vaccines since the 1940s
[10]. Annual influenza immunization for the active force began
in the 1950s and total force (active and reserve components)
influenza immunization remains a mandatory yearly requirement
barring a contraindicating condition [10,18]. Continually since the
2003–2004 influenza season, military immunization policies have
called for preferential use of LAIV for all eligible service mem-
bers, with TIV reserved for those not eligible to receive LAIV
[19–21]. Recommendations for preferential use of LAIV over TIV
originated from greater demand for influenza vaccine during the
2003–2004 season and the need to maintain adequate supplies of
TIV for high risk populations not eligible to receive LAIV [22,23].
Although policies emphasize the use of LAIV, there have not been
any investigations on the efficacy or effectiveness of this vaccine
0264-410X/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
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in comparison to TIV among military service members. The few
population-based military studies that investigated influenza vac-
cine effectiveness were conducted among military basic trainees
assessing TIV only during the 2003–2004 season and TIV and LAIV
during the 2005–2006 season. These studies found very high vac-
cine effectiveness (92–94%) against laboratory confirmed influenza
[24,25].
The U.S. military population provides a unique group to inves-
tigate and compare influenza vaccines, because it is primarily
comprised of healthy adults who are annually immunized against
influenza. In the general U.S. population, healthy young adults are
not considered at high risk for significant influenza morbidity, so
they are not targeted for immunization. As a result, this group has
the lowest immunization rates compared to other age groups,mak-
ing it difficult to investigate and compare influenza vaccines in this
groupoutside of a clinical trial [26,27]. In order to evaluate howwell
LAIV and TIV protect against influenza-like illness (ILI) among the
adult population and to better informU.S.military influenza immu-
nization policy, we conducted this analysis for the 2005–2006 and
2006–2007 influenza seasons.
2. Materials and methods
2.1. Study design
Thiswas a retrospective cohort study. Twoconsecutive influenza
seasons, 2005–2006 and 2006–2007, were investigated. The
Defense Medical Surveillance System (DMSS) contains demo-
graphic, occupational, immunization, and medical encounter data
for U.S. military service members [28]. Using DMSS, we identified
the eligible cohorts for each year of the study. The cohorts consisted
of service members in the active component of the U.S. Army, Air
Force, Navy, or Marine Corps, who were stationed in the U.S. and
who had documentation of receiving only one dose of either LAIV
or TIV from 1 September to 30 April during the season of inter-
est. Determination of which vaccine a service member receives is
typically not dependant on self-selection, but driven by service spe-
cific policies and vaccine ordering, availability of vaccines (early
in the season one vaccine type may be available before the other
type or shortages could affect vaccine selection by the clinic), and
pre-existing exclusions for one vaccine type (age, contraindicating
illnesses). To ensure that our study population consisted of service
members eligible to receive either vaccine, service members 50
years of age or older and those who were pregnant at the time of
immunization were excluded from the cohort.
Person-time at risk was calculated by summing the time from
14 days after influenza immunization to the end of the surveillance
period (30 April) or the occurrence of a right censoring event. Right
censoring events included overseas deployment, termination of
military service, or change in status from active to reserve or guard
component. Affected individuals were not considered “at risk” for
30 days after each ILI; hence, the 30 days after each ILIwas excluded
from the person-time at risk.
2.2. Identification of influenza-like illness
DMSS was used to identify ILIs among the study cohorts. An
ILI event was defined as an outpatient or inpatient medical visit
which resulted in an ICD-9 diagnostic code (Table 1) consistent
with an ILI. The ICD-9 codes selected for this study were previously
shown to be associated with culture-confirmed influenza illnesses
among the U.S. military population [29]. To be counted as an ILI
event, the medical encounter had to occur during the follow-up
period which began 14 days after immunization and ended on 30
April or the date of a right censoring event. Medical visits occur-
Table 1
ICD-9-CM codes used to identify influenza-like illness.
ICD-9-CM code Description
79.99 Viral infection, NOSa
382.9 Otitis media, NOSa
460.0 Nasopharyngitis, acute
461.9 Acute sinusitis, unspecified
465.8 Upper respiratory infection, other multiple sites
465.9 Upper respiratory infection, acute NOSa
466.0 Bronchitis and bronchiolitis, acute
486.0 Pneumonia, organism unspecified
487.0 Influenza with pneumonia
487.1 Influenza with other respiratory manifestations
487.8 Influenza with other manifestations
490.0 Bronchitis, not specified as acute or chronic
780.6 Fever
786.2 Cough
a NOS: not otherwise specified.
ring within 30 days of a primary visit were considered the same ILI
event.
2.3. Statistical analysis
Three separate analytic planswere used for this study to address
possible bias due to changing influenza activity during the season
and timing of vaccine administration. The first method, the “Con-
tinuous Cohort”, included the entire eligible cohort. People could
enter the study cohort at any point during the influenza season
when they received the influenza vaccine. The second method, the
“November Cohort”, included only people immunized during the
month of November. For these first two methods, every new ILI
event (30 days window applied) was counted as an outcome. The
third method, the “Intense Cohort”, included only people immu-
nized from 1 September to 14 days prior to the start of the intense
influenza period. Based on U.S. national data from the Centers for
Disease Control and Prevention (CDC), the intense influenza period
was defined as the 8 weeks with the highest percentage of iso-
lates testing positive for influenza surrounding the peak influenza
week (defined as the week with the highest percentage of tests
positive for influenza) [30–32]. The intense influenza period was
defined as 29 January 2006 through 01 April 2006 and 21 January
2007 through 24 March 2007 for the 2005–2006 and 2006–2007
influenza seasons, respectively. For the intense cohort, only the first
ILI occurring during the intense influenza periodwas counted as an
outcome. Person-time was censored on the date of the ILI medical
visit.
For all analyses, recruits and non-recruits were analyzed sep-
arately due to differences in baseline risk of ILI and strong effect
modification between recruit status and immunization received.
Recruit status was defined at the time of immunization. In addi-
tion, recruits were stratified by service. Navy and Marine recruits
were almost entirely immunized with TIV, therefore compar-
isons between the two vaccines could not be made in these
populations. This was also seen for the Air Force recruit Novem-
ber cohort, which consisted mainly of LAIV recipients for the
2005–2006 influenza season and TIV recipients for the 2006–2007
season.
The incidence of ILI per 1000 person-years (PY) was calculated
for people who received either LAIV or TIV. The crude incidence
rate ratio (IRR) and 95% confidence intervals (CI) were calculated
comparing the ILI incidence in the LAIV group vs. the TIV group.
In order to control for confounders, a Poisson regression model
was used to estimate the adjusted IRR and 95% CI. Confidence
intervals that did not include 1.0 were considered statistically sig-
nificant at an ´=0.05 level of significance. The model included
covariates that were considered a prior to be risk factors for
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Table 2
Demographic and service characteristics of the non-recruit and recruit cohorts by season and immunization group.
Characteristic 2005–2006 influenza season 2006–2007 influenza season
Non-recruits Recruits Non-recruits Recruits
TIV LAIV TIV LAIV TIV LAIV TIV LAIV
Total cohort (N) 565,165(%) 136,588(%) 49,990(%) 20,335(%) 372,117(%) 384,974(%) 30,420(%) 17,547(%)
Age (years)
17–19 5.5 9.0 49.1 45.7 5.6 7.6 46.7 43.3
20–29 56.8 54.2 49.4 51.5 57.1 56.5 50.7 51.7
30–39 27.7 27.5 1.5 2.7 27.4 26.7 2.4 4.6
40–49 10.1 9.3 <0.1 <0.1 10.0 9.1 0.2 0.4
Sex
Male 85.6 85.0 83.6 79.4 86.0 85.7 82.0 81.1
Race-ethnicitya
White 63.9 66.5 68.0 68.6 64.2 65.4 71.7 69.6
Black 17.5 17.1 12.2 15.2 16.4 17.6 14.8 15.6
Hispanic 9.8 8.8 10.0 9.6 10.1 9.2 6.6 9.1
Other/unknown 8.9 7.7 9.9 6.7 9.5 7.8 7.0 5.8
Service
Army 34.1 61.6 29.9 77.7 26.8 53.9 35.8 81.6
Air Force 35.7 35.0 23.0 21.7 32.0 32.7 42.1 16.8
Marine Corps 9.9 1.0 21.3 0.6 14.5 7.3 12.3 0.2
Navy 20.3 2.4 25.8 0.0 26.8 6.1 9.8 1.4
Number of medical visits in previous year
0 11.5 9.0 99.8 96.5 5.8 4.1 99.7 99.6
<10 66.9 68.3 0.2 3.5 50.3 48.5 0.4 0.4
10–19 15.2 16.0 <0.1 0.0 26.2 28.4 0.0 <0.1
20+ 6.4 6.7 0.0 0.0 17.7 19.2 0.0 <0.1
Ever hospitalized
Yes 19.9 19.6 N/A N/A 19.2 19.2 N/A N/A
Other immunization on same day
Yes 20.3 17.5 91.3 88.2 15.1 19.5 97.0 91.1
Other immunizations in previous 1–30 days
Yes 7.6 6.6 20.3 38.3 6.4 7.9 32.6 64.5
Flu vaccine given in previous influenza season
Yes 45.6 50.4 N/A N/A 33.0 61.5 N/A N/A
Percentages may not add up to 100% due to rounding. LAIV, live attenuated influenza vaccine; TIV, trivalent influenza vaccine.
a Race-ethnicity was self-reported and categorized in the DMSS. “Other” included Asian/Pacific Islander, American Indian/Alaska Native, and other.
influenza or vaccine selection and included sex, age at immuniza-
tion, service component, race-ethnicity, region, number of medical
visits in the past year, ever hospitalized (yes/no), influenza immu-
nization during previous influenza season (yes/no), additional
immunizations received on the same day as the influenza immu-
nization (yes/no), and additional vaccines received 1–30 days prior
to the influenza immunization (yes/no). Region was based on
the location of the service member at the time of immuniza-
tion. Regions were defined as New England (Connecticut, Maine,
Massachusetts, New Hampshire, Vermont, Rhode Island), Mid-
Atlantic (New Jersey, New York, Pennsylvania), East North Central
(Illinois, Indiana, Michigan, Ohio, Wisconsin), West North Cen-
tral (Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota,
South Dakota), South Atlantic (Delaware, Florida, Georgia, Mary-
land, North Carolina, South Carolina, Virginia, Washington, D.C.,
West Virginia), East South Central (Alabama, Kentucky, Mis-
sissippi, Tennessee), West South Central (Arkansas, Louisiana,
Oklahoma, Texas), Mountain (Arizona, Colorado, Idaho, Mon-
tana, Nevada, New Mexico, Utah, Wyoming), and Pacific (Alaska,
California, Hawaii, Oregon, Washington). In addition, for the
non-recruits, separate analyses were conducted for each age cat-
egory. SAS 9.1 (SAS Institute, Cary, NC, USA) was used for the
analysis.
This investigation was conducted for military public health
surveillancepurposes andnot research, therefore it didnot undergo
institutional review board examination. No external funding was
received to conduct this investigation.
3. Results
3.1. Study population
For the 2005–2006 influenza season, we identified 701,753
non-recruits and 70,325 recruits. Among the non-recruits, 80.5%
received TIV and 19.5% received LAIV. Among the recruits, 71.1%
and 28.9% received TIV and LAIV, respectively. Although the TIV
and LAIV groups appear demographically similar for both the
non-recruit and recruit populations, the population demographic
differences were statistically significant (Table 2). This mainly
reflects the large sample sizes of the populations and is not uncom-
mon with studies of this size. However, of note, Soldiers made up
the majority of the LAIV group for both recruits and non-recruits,
where as the TIV group consisted of a similar percentage of Soldiers,
Airmen, and Sailors. In addition, among the recruits, LAIV recipients
weremore likely to have had other immunizations administered in
the 1–30 days prior to their influenza immunization.
For the 2006–2007 influenza season, the cohort consisted of
757,091 non-recruits and 47,967 recruits. TIV and LAIV immuniza-
tions were more evenly distributed for the 2006–2007 season
with 49.2% and 63.4% of the non-recruits and recruits, respec-
tively, receiving TIV. Consistent with the prior year, the LAIV group
consisted of a high percentage of Soldiers, the TIV group was
moveevenlydistributedwithSoldiers, Airmen, Sailors andMarines,
and recruits receiving LAIV were more likely to have received
other immunizations in the 1–30 days prior to the influenza
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Table 3
Crude incidence rates of the non-recruit and recruit cohorts by demographic characteristics and immunization group, 2006–2007.
Characteristic Non-recruits Recruits
TIV LAIV TIV LAIV
Total Cohort (N) 372,117 384,974 30,420 17,547
IR (95% CI)b IR (95% CI)b IR (95% CI)b IR (95% CI)b
Age (years)
17–19 321 (307–336) 482 (468–496) 1846 (1796–1896) 1363 (1314–1411)
20–29 239 (235–243) 367 (363–371) 2152 (2096–2208) 1427 (1381–1474)
30–39 265 (259–271) 342 (336–348) 2478 (2166–2790) 1860 (1683–2037)
40–49 288 (278–298) 317 (307–326) 2632 (1369–3896) 2007 (1395–2619)
Sex
Male 221 (218–223) 321 (318–325) 1898 (1858–1937) 1301 (1266–1335)
Female 472 (461–482) 608 (597–618) 2558 (2451–2664) 1933 (1843–2023)
Race-ethnicitya
White 268 (265–272) 371 (367–375) 2005 (1961–2050) 1464 (1423–1504)
Black 244 (237–251) 344 (336–351) 1970 (1874–2065) 1289 (1212–1366)
Hispanic 215 (207–224) 360 (349–371) 2012 (1873–2151) 1479 (1364–1593)
Other 221 (210–231) 364 (351–378) 2033 (1896–2170) 1152 (1032–1272)
Service
Army 278 (272–284) 361 (356–365) 2504 (2422–2585) 1616 (1576–1655)
Air Force 400 (393–406) 412 (407–418) 2061 (2001–2121) 711 (661–761)
Marine Corps 177 (171–184) 157 (149–165) 1145 (1084–1207) 2285 (1440–3129)
Navy 129 (125–133) 332 (320–344) 2189 (2092–2286) 2988 (2418–3559)
Number of medical visits in previous year
0 197 (186–209) 393 (376–410) 2011 (1973–2048) 1421 (1388–1454)
<10 176 (172–179) 383 (279–287) 508 (283–733) 912 (553–1271)
10–19 276 (270–282) 367 (361–373) 0.0 0.0
20+ 477 (467–487) 558 (549–567) 0.0 0.0
Ever hospitalized
No 231 (228–234) 351 (347–354) N/A N/A
Yes 359 (351–367) 418 (410–425) N/A N/A
Other immunization on same day
No 250 (246–253) 364 (361–368) 1521 (1371–1671) 1069 (978–1160)
Yes 299 (290–309) 363 (355–371) 2022 (1983–2060) 1456 (1421–1492)
Other immunizations in previous 1–30 days
No 256 (253–259) 362 (359–366) 2147 (2100–2195) 1594 (1535–1653)
Yes 253 (241–264) 383 (370–395) 1721 (1661–1780) 1326 (1286–1365)
Flu vaccine given in previous season
No 273 (269–277) 365 (360–371) N/A N/A
Yes 226 (221–231) 363 (359–367) N/A N/A
IR= incidence rate; CI = confidence intervals; LAIV= live attenuated influenza vaccine; TIV= trivalent influenza vaccine.
a Race-ethnicity was self-reported and categorized in the DMSS. “Other” included Asian/Pacific Islander, American Indian/Alaska Native, and other.
b Crude incidence rate per 1000 person-years.
immunization (Table 2). In addition, non-recruit LAIV recipients
were more likely than TIV recipients to have been vaccinated for
influenza during the previous influenza season.
3.2. ILI incidence
Thecrude incidenceof ILIs stratifiedbyvariousdemographic and
service characteristics for the 2006–2007 influenza season is pre-
sented in Table 3. Overall, crude ILI incidence rates were 5–9 times
higher and 2–16 times higher comparing recruits to non-recruits
for TIV recipients and LAIV recipients, respectively. Females con-
sistently had higher crude rates than males. Among non-recruits,
Airmen had the highest crude rates compared to the other services
regardless of vaccine group. Similar distributions were seen for the
2005–2006 season (Supplemental Table 1).
The timing of LAIV and TIV immunizations, distribution of ILI
events, distributionof CDC influenza confirmed specimens, anddis-
tribution of censoring events for the continuous cohort for both
seasons are presented in Fig. 1 [31,32]. For the non-recruits, the
majorityof influenza immunizationsoccurredby theendofDecem-
ber for both season. Since recruits were continuously entering
service throughout the influenza season, recruit immunizations
were more evenly distributed throughout each season. For both
seasons, peak ILI activity occurred during the first 2 months of the
new year, although the 2006 season did have a slightly lower peak
during November and December. Censoring events for the both the
recruits andnon-recruitswere relativelyevenlydistributed through
each season.
3.2.1. Non-recruits
For the 2005–2006 continuous and November cohorts, the ILI
incidence per 1000 PY was 358.7 and 361.3 among LAIV recipients
and 271.6 and 291.5 for TIV recipients, respectively. For the intense
cohort, the ILI incidence was higher at 407.5 per 1000 PY and 315.2
per 1000PY for LAIV andTIV immunized, respectively. Regardless of
the cohort, the ILI incidence among LAIV recipientswas higher than
TIV recipients, with an adjusted IRR and 95% CI of 1.17 (1.14–1.20)
(Table 4).
Incidence rates for the 2006–2007 influenza season were sim-
ilar to rates for the 2005–2006 season, however the magnitude of
the IRRs was greater (Table 4). The ILI incidence among LAIV recip-
ients was higher than TIV recipients for all three analysis cohorts
for the 2006–2007 influenza season (adjusted IRR [95% CI]: 1.25
(1.23–1.27) to 1.33 (1.30–1.36)).
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Fig. 1. Timing and distribution of live attenuated (LAIV) and inactivated (TIV) influenza immunizations, incident influenza-like illnesses (ILIs), CDC flu positive specimens,
and censoring events for non-recruits (A) and recruits (B) for the 2005–2006 and 2006–2007 influenza seasons.
For the age stratified analysis, IRRs decreased with increasing
age category. The highest IRRs were in the 17–19-year-old age cat-
egory and lowest IRRs were in the 40–49-year-old age category for
both seasons and for all cohorts (Supplemental Table 2).
3.2.2. Recruits
Table 5 combines the results of the 2005–2006 and 2006–2007
influenza seasons for the Army and Air Force recruits. Unlike the
non-recruit population, recruit LAIV recipients had statistically sig-
nificantly lower ILI incidence rates than TIV recipients. This finding
was consistent for both seasons and services and all cohorts (where
sample size was sufficient to perform calculations) except for the
2006–2007 Air Force intense cohort, which did not reach statistical
significance (IRR and 95% CI: 0.82 (0.62–1.09)). LAIV recipients had
a relative reduction in adjusted ILI incidence of 22–51% and 18–47%
compared to TIV recipients for the 2005–2006 and 2006–2007 sea-
sons, respectively.
4. Discussion
Over two consecutive influenza seasons, we were able to fol-
low large cohorts of service members to assess how well LAIV and
TIV protected against ILI. Our findings of greater protection from
ILI with LAIV compared to TIV for recruits and slightly greater pro-
tection with TIV compared to LAIV for non-recruits were initially
surprising.However, after considerationof these resultswehypoth-
esize that several factors may be contributing to this difference.
Among the recruit population, for both influenza seasons, we
found a significant protective effect of LAIV against ILI compared
to TIV recipients. Two possible explanations for these finding are
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Table 4
Crude and adjusted incidence rate ratios comparing LAIV to TIV among non-recruits by analytical cohort and influenza season.
Analysis cohort 2005–2006 Influenza season 2006–2007 Influenza season
ILI incidence
rate (per 1000
person-years)
Crude
incidence rate
ratio (95% CI)
LAIV vs. TIV
Adjusted
incidence rate
ratio (95% CI)a
LAIV vs. TIV
ILI incidence
rate (per 1000
person-years)
Crude
incidence rate
ratio (95% CI)
LAIV vs. TIV
Adjusted
incidence rate
ratio (95% CI)a
LAIV vs. TIV
Continuous cohort
LAIV recipients 358.7 1.32 (1.30–1.34) 1.17 (1.15–1.18) 363.8 1.42 (1.40–1.44) 1.25 (1.23–1.27)
TIV recipients 271.6 – – 255.7 – –
November cohort
LAIV recipients 361.3 1.24 (1.21–1.27) 1.17 (1.14–1.20) 353.1 1.44 (1.41–1.48) 1.28 (1.24–1.31)
TIV recipients 291.5 – – 244.9 – –
Intense cohort
LAIV recipients 407.5 1.29 (1.26–1.33) 1.17 (1.14–1.20) 455.4 1.49 (1.47–1.53) 1.33 (1.30–1.36)
TIV recipients 315.2 – – 305.4 – –
ILI, influenza-like illness; LAIV, live attenuated influenza vaccine; TIV, trivalent influenza vaccine; CI, confidence intervals.
a Adjusted for age, sex, race-ethnicity, service, region, ever hospitalized, number of medical visits in previous year, receipt of other immunizations on same day or 1–30
days prior to influenza immunization, and receipt of influenza immunization in previous influenza season.
that the recruit population has an intense burden of respiratory
disease compared to non-recruits and recruits may also have a dif-
ferent immune response to immunization compared to routinely
immunized non-recruits. Our recruit findings were similar to what
has been shown for studies comparing the vaccines in children.
Belshe et al. found a 54.9% reduction in the number of culture-
confirmed influenza cases among children 6–59 months for LAIV
compared to TIV recipients [1]. This effect is larger, but still similar
to our finding of approximately a 22–51% reduction in ILIs among
recruits. Although the recruit population is made up of people
17–42 years old, the majority of recruits (60–65%) were 20 years of
age or younger. This age group falls into the category with the low-
est immunization rates in the United States, mostly likely because
they were not persons for whom annual immunization was rec-
ommended [26,27]. We suspect that the majority of recruits were
not immunized against influenza in the years prior to joining the
service and not at high risk for severe complications of influenza
disease. This may lead to some recruits having an immune system
that is relatively naive to influenza and to have a different immune
response compared to that of amore seasoned servicememberwho
has received multiple annual influenza immunizations. Previous
studies have found LAIV to elicit a more robust immune response
and increased viral replication in unprimed subjects [33–36]. These
findings may explain the higher protection of LAIV compared to
TIV in recruits. With the new 2008 recommendation for annual
influenza immunization of children 5–18 years of age by the Advi-
sory Committee on Immunization Practices, it will be important
to assess if prior immunization rates among recruits are increas-
ing and whether these increases effect the robust ILI protection we
observed with LAIV [37].
Table 5
Crude and adjusted incidence rate ratios comparing LAIV and TIV among recruits by service and analytical cohort: 2005–2006 and 2006–2007 influenza seasons.
Analysis cohort ILI incidence
rate (per 1000
person-years)
Crude
incidence rate
ratio (95% CI)
LAIV vs. TIV
Adjusted
incidence rate
ratio (95% CI)a
LAIV vs. TIV
ILI incidence
rate (per 1000
person-years)
Crude
incidence rate
ratio (95% CI)
LAIV vs. TIV
Adjusted
incidence rate
ratio (95% CI)a
LAIV vs. TIV
Army Air force
2005–2006 Season
Continuous cohort
LAIV recipients 1458.7 0.53 (0.52–0.55) 0.53 (0.51–0.55) 1310.8 0.56 (0.54–0.59) 0.64 (0.59–0.69)
TIV recipients 2735.2 2325.9
November cohort
LAIV recipients 1326.2 0.94 (0.87–1.03) 0.78 (0.71–0.87) Not applicable− counts
too smallTIV recipients 1406.0
Intense cohort
LAIV recipients 1736.5 0.80 (0.74–0.88) 0.74 (0.67–0.81) 701.7 0.34 (0.30–0.39) 0.49 (0.41–0.59)
TIV recipients 2158.7 2073.4
2006–2007 Season
Continuous cohort
LAIV recipients 1615.7 0.65 (0.62–0.67) 0.66 (0.63–0.69) 711.2 0.35 (0.32–0.37) 0.53 (0.47–0.60)
TIV recipients 2503.8 2061.1
November cohort
AIV recipients 1668.2 0.64 (0.58–0.71) 0.73 (0.60–0.89) Not applicable− counts
too smallTIV recipients 2594.6
Intense cohort
LAIV recipients 2004.3 0.71 (0.61–0.83) 0.71 (0.58–0.86) 845.9 0.79 (0.69–0.90) 0.82 (0.62–1.09)
TIV recipients 2810.0 1072.3
LAIV, live attenuated influenza vaccine; TIV, trivalent influenza vaccine; ILI, influenza-like illness; CI, confidence intervals.
a Adjusted for age, sex, race-ethnicity, service, region, number of medical visits in previous year, and received other vaccines on same day or 1–30 days prior to influenza
vaccine.
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The intense burden of respiratory disease found in the recruit
setting may also play a role in the differences between recruits and
non-recruits. Crowded living conditions, stressful environments,
and the continuous entry of people from throughout the United
States into this population make this setting ideal for the spread
of respiratory pathogens [38,39]. Not surprisingly, we found rates
of ILIs to be 2–16 times higher among the recruits compared to
the non-recruits depending on the service, immunization group,
analysis cohort, and year of study. Previous studies of the recruit
population have reported significant burden of respiratory disease
and outbreaks of disease, due primarily to adenovirus, influenza,
respiratory syncytial virus, and bacterial infections [14,18,40–43].
The high burden and mixing of a variety of respiratory pathogens
in this setting may alter the protective effect of vaccines. If
influenza plays a role in subsequent viral or bacterial infections,
then increased protection by LAIV may appear even greater in this
recruit setting. In addition, the broad case definition of ILI may
encompass these other acute respiratory pathogens.
The lower incidence of ILIs among non-recruit TIV recipients
compared to LAIV recipientswas similar tomost reports among the
general U.S. adult population. In a randomized, placebo-controlled
challenge study, Treanor et al. reported a higher protective efficacy
of LAIV (85%) compared to TIV (71%) among adults but this differ-
ence lacked statistical significance [6]. However, Nichol et al. found
LAIV to be statistically significantly effective at preventing severe
febrile illnesses and febrile upper respiratory tract illnesses com-
pared to placebo [8]. Another randomized, placebo-controlled trial
by Ohmit et al., found a higher absolute efficacy for TIV for culture
or real-time PCRpositive influenza (75% and 16%) compared to LAIV
(48%and8%) forboth the2004–2005and2005–2006 influenza sea-
sons among adults, butwith overlapping confidence intervals [5,7].
TIV has also been reported by Bridges et al. to be 86% efficacious
against laboratory confirmed influenza when compared to placebo
[9]. Although our findings are consistent with these previous
studies in adults, we were able to show statistically significant dif-
ferences at an ´=0.05 level between LAIV and TIV protection from
ILI. Onepossible explanation for this finding in our non-recruit pop-
ulation is high annual influenza immunization rates. Pre-existing
antibody from multiple years of influenza immunizations may be
playing a role in reducing the replication and antibody response to
LAIV [33,34,36,44–47].However, ourfindings of an inverse relation-
ship between LAIV to TIV IRRs and age, as shown in (supplemental
Table 2), is counter to the hypothesis that older age groups would
have received more influenza immunizations and therefore have
greater interference of pre-existing antibody with LAIV. One expla-
nation of this finding is that older age may not directly correlate
with more years in military service or more influenza immuniza-
tions. However, we feel these findings really point out that the
interaction between LAIV and the immune system is multifaceted
and requiresmoredetailed investigationsof the innate andadaptive
immune responses to influenza immunizations.
An additional issue that could be playing a role in the differ-
ence between recruit and non-recruit findings may be differences
in circulating influenza strains. Although we did not have data to
specifically identify which strains were circulating in our popula-
tions, a previous study has reported differing vaccine effectiveness
for LAIV and TIV when looking at influenza A and B viruses sepa-
rately. The study by Ohmit et al., although under-powered for the
strain specific assessment, reported a reduced protection of LAIV
against influenza B viruses [5]. Although influenza B viruses were
the minority, based on CDC data, they were present during both
seasons, typically later in the season [29,30]. If non-recruits were
more likely to be exposed to influenza B viruses than recruits, then
it may partially explain the differences we saw with LAIV.
The data used for this investigation present several limitations.
The principal limitation is our use of ICD-9 codes consistent with
ILI for the outcome of interest instead of laboratory confirmed
influenza illness. By using this less specific case definition, it is
likely some of the events were caused by viral or bacterial respi-
ratory pathogens other than influenza, and we overestimated the
true incidence of influenza. However, to minimize this risk, we
chose to use ICD-9 codes that had previously been shown in a very
similar population to be most associated with culture-confirmed
influenza cases [29]. A benefit of this methodology is that it allows
for assessment of the vaccines on a large population scale which
wouldbe infeasible for a culture-confirmed study. Additionalweak-
nesses include a lack of smoking status, lack of knowledge about
the number of children in the household, and lack of medical and
immunization data prior to entry into military service. We were
unable to determine whether recruits were immunized or infected
with influenza in the year prior to entry into the service or to
control for potential confounders such as past medical history or
medical care usage patterns. However, in order to enter military
service, applicantsmustmeet certain physical andmedical eligibil-
ity standards, which should decrease the likelihood of inclusion of
recruits with significantmedical conditions thatwould put them at
higher risk for ILI [48,49]. Selection bias may have occurred for the
November cohort, butwas necessary to be able to control for differ-
ences in the timing of LAIV and TIV administration. Using the CDC
national influenza data to determine the windows for the intense
cohorts may not accurately account for region and military dif-
ferences in peak influenza activity. Although military specific data
were not available, we did determine region specific windows for
peak influenza activity using the CDC regional data and performed
regional intense cohort analyses. The findings from these regional
analyses were similar to the overall intense cohorts presented here
(data not shown). The possibility for residual confounding and/or
unmeasured confounding is also a limitation to the study.
Our results support continued immunization and preferential
use of LAIV for the recruit population. Among adults regularly
immunized against influenza and in a non-recruit setting, our
findings of a slightly higher effectiveness with TIV favor immu-
nization with this vaccine. Consideration of these findings should
be made when developing influenza immunization policies. This
study was strengthened by the consistency of findings using mul-
tiple study cohorts and over multiple influenza seasons. Additional
studies of this nature are needed among adults to see if these find-
ings are generalizable to the general U.S. population. In addition,
investigation of the role of annual influenza immunizations in the
adult population on the immunogenicity and viral replication of
LAIV are needed. Continued assessment of these vaccines in sub-
sequent influenza seasons is essential, especially during years of
sub-optimal vaccine strain match and more significant seasons to
assess how well these vaccines perform.
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